What is iNRT?
What is iNRT?
This section provides information for health professionals who want to know more about iNRT (inhaled nicotine replacement therapy), otherwise referred to as e-cigarettes or vaping, and the scientific evidence underpinning it. Vaporisers (vapes or e-cigarettes) are battery-powered devices that heat a liquid (potentially containing nicotine) into an aerosol for inhalation. When prescribed for therapeutic purposes, iNRT is prescribed as a less harmful substitute for smoking
iNRT provides smokers with a similar experience that they're familiar with, by addressing the behavioural (hand-to-mouth action), sensory (‘throat hit’, inhaling and exhaling a visible ‘smoke’) and social aspects of the smoking ritual, but without most of the harmful toxins found in smoke.
Complete cessation of all tobacco and nicotine use is always the preferred goal. When complete cessation by your patient is not able to be achieved however, iNRT can be prescribed as a form of tobacco harm reduction (THR) which aims to reduce the harm associated with smoking, without necessarily ceasing nicotine usage.
The Royal College of Physicians report states that although the nature and extent of any long-term health effects of inhaling nicotine remain uncertain, because there is no experience of such use other than from cigarettes, it is inherently unlikely that nicotine inhalation itself contributes significantly to the mortality or morbidity caused by smoking. The main culprit is smoke, and if nicotine could be delivered effectively and acceptably to smokers without smoke, most if not all of the harm of smoking could potentially be avoided.
How are Nicovape’s iNRT products different to other electronic cigarettes?
In principle, Nicovape aims to be more of a stop smoking service than simply another electronic cigarette company. Hence we are aiming to change the perception of our iNRT products to reflect the fact that our devices and high nicotine concentration liquids are designed with one objective in mind: to help smokers quit.
iNRT is how we plan to achieve this. While we appreciate that no therapy is without risk, our products are inherently designed to minimise the risks and maximise the effectiveness and are only delivered under medical supervision to patients who have failed to quit smoking using standard treatments.
We know from clinical studies on standard nicotine replacement therapy options, and the epidemiological evidence of the continuous usage of high nicotine products for decades in Sweden in smokeless tobacco (snus), that nicotine itself is a largely benign substance with risks that are comparable to caffeine.
We produce among the safest vapourised nicotine products on the market today combined with the most effective nicotine delivery we can achieve, in a delivery format that smokers enjoy using so that we can help even the most hardened and pre-contemplative smokers quit, by substitution.
Our aim is to make it as easy as possible to switch from smoking, with its thousands of cancer and emphysema causing toxins, to a product that as a category is already estimated by the Royal College of Physicians in the UK to have less than 5% of the risk profile of smoking. Our intention is for our products to go even further than this and minimise toxins and emissions to the lowest levels possible, without detracting from the satisfaction smokers need to be able to switch entirely away from smoking.
Our iNRT products use high strength nicotine salt technology which enable higher concentrations of nicotine to be delivered, and with a comparably rapid bioavailability as cigarettes to assist with quitting and prevent relapse or dual use. We offer a small range of responsible, yet enjoyable flavours to replace the enjoyment of smoking with the enjoyment of vaping, again to assist with quitting and prevent relapse or dual use. Our products feature continuous temperature control with one of the most studied and inert coil metals available. Along with our low-power delivery profile and high nicotine concentration formulations, we ensure that we satisfy the smokers needs with only the minimum amount of vapor produced and at the lowest temperature possible.
We intend to subject our iNRT products to the most rigorous independent scientific analysis to continually improve both their safety and effectiveness. Our products already utilize the highest quality e-liquid on the market, produced in our ISO5, GMP certified eliquid manufacturing facility in New Zealand. Our goal is to develop devices and accompanying liquid formulations that under every measure tested, will achieve a toxicant profile that represents less than 1% of the comparable risk of smoking.